Drugs and Devices

FDA approves Mekinist in combination with Tafinlar for advanced melanoma

On Jan. 10, the U.S. Food and Drug Administration (FDA) announced it had approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable or metastatic. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares